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IntroductIon
Nonalcoholic fatty liver disease (NAFLD) is one of the most 
common liver diseases, and even though the exact preva-
lence is not known, it is estimated to affect about 30% of the 
 general population in urban communities (1) and about 70% 
of obese individuals (2). Per definition, it occurs in individu-
als who consume minimal amounts of alcohol, and it is fre-
quently associated with the features of the metabolic syndrome 
including obesity, insulin resistance/diabetes, hypertension, 
and hyperlipidemia (3,4). The spectrum of liver histology in 
NAFLD ranges from steatosis to nonalcoholic  steatohepatitis 
(NASH) which is characterized by macrovesicular steato-
sis with various degrees of lobular inflammation, hepatocyte 
 ballooning, and predominantly centrilobular fibrosis. About 
15% of patients with NAFLD will develop NASH, which ulti-
mately may cause cirrhosis and hepatocellular carcinoma (5). 
Leptin is an  adipokine, and is implicated in the patho genesis of 
NASH, due to its important modulatory effects on the regula-
tion of body weight, appetite and in preventing lipid accumu-
lation in the skeletal muscle, pancreas, and liver (6,7). Obesity 
is strongly associated with increased circulating leptin concen-
trations. However, obese patients often develop leptin resist-
ance which aggravates the metabolic defects (8). The exact 
mechanism of the development of leptin resistance in obese 
patients is unknown but it is suspected that sequestration of 
circulating free leptin may play a role (8). Of interest, leptin has 
been shown to have profibrogenic effects on the liver in in vitro 
and in animal models (9–11), suggesting a potential role of 
this hormone in the pathogenesis and progression of fibrosis 
in NASH. Despite this, no study in human subjects has found 
a convincing correlation between circulating leptin levels and 
stage of fibrosis and the role of leptin in hepatic fibrogenesis in 
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humans are still debated (12–14). In this context, increasing 
attention has been devoted to the soluble leptin receptor (SLR), 
a major leptin-binding protein in the serum, generated by the 
proteolytic cleavage of the ectodomain of the membrane-
bound leptin receptor. However, the exact role of SLR in the 
regulation of leptin bioavailability remains unknown (15,16). 
SLR is thought to be produced mainly by the liver (17) there-
fore changes of SLR in the circulation may reflect the patho-
genic changes during NASH development.
In this study, we described a positive correlation of SLR with 
the histological stage of NAFLD/NASH in diabetic, morbidly 
obese patients. These data may have future implications with 
regard to the role of SLR in the development leptin resistance 
in NASH.
Methods and Procedures
Patients
Data and samples were collected from December 2005 to March 2008 
on patients undergoing bariatric surgery at University of California 
Davis Medical Center (Sacramento, CA), who consented for the study. 
A questionnaire was answered by the potential participants at the initial 
evaluation regarding their liver disease history. All patients had intra-
operative surgical core liver biopsies of the lateral right hepatic lobe, 
according to a standard surgical protocol. We reviewed individual 
medical charts for demographics, medical history and physical exami-
nation, preoperative laboratory data, and risk factors for the meta-
bolic syndrome (BMI, hypertension, hyperlipidemia, type 2 diabetes 
 mellitus). Patients with clinical or radiological evidence of cirrhosis 
were not considered  candidates for bariatric surgery and, therefore 
were not included in our analysis. Potential etiologies for other chronic 
liver diseases were excluded by medical history, hepatitis A, B, and C 
serologies, histology, ceruloplasmin, transferrin saturation, and α-1 
antitrypsin level. Diagnosis of hypertension was made according to the 
guideline set by Joint National Committee 7 (18). Diagnosis of hyper-
lipidemia was made following the guideline set by National Cholesterol 
Education Program III (19). The BMI was calculated as the weight 
in pounds divided by the square of the height in feet. The study was 
conducted in accordance with the ethical standards of the Helsinki 
Declaration of 1975 (as revised in 1983). This study was approved by 
University of California Davis Medical Center institutional review 
board (protocol #200513532-3).
Biochemical assays
Once informed consent was obtained, all participants had blood 
 samples drawn before the surgery (09:00–11:00 am), after an over-
night fast. The blood samples were then immediately put on ice, and 
plasma was obtained by centrifugation at 1,400 g for 10 min at 4 °C. The 
plasma was spun again at 2,700 g for 10 min at 4 °C, and the recovered 
plasma was stored in aliquots at −80 °C. The EDTA-plasma was ana-
lyzed for glucose, insulin, total leptin (RIA; Linco Research, St Charles, 
MO), and SLR (ELISA; Diagnostic Systems Laboratories, Webster, TX). 
The homeostasis model of assessment insulin resistance (HOMAIR) 
was used as an index of insulin resistance. HOMAIR was calculated 
using the standard formula: (fasting glucose (ml/dl) × fasting insulin 
(μU/ ml))/405. Free leptin index (FLI) index was calculated as the ratio 
of leptin to SLR.
histology
The liver biopsy specimens were reviewed blindly by a hepatopathologist 
for the presence of macrovesicular steatosis, fibrosis, and neutrophilic lob-
ular inflammation according to the Brunt’s scoring system (20). Steatosis 
was graded on a four-point scale: grade 0: steatosis involving <10% of 
hepatocytes; grade 1: steatosis up to 30%; grade 2: steatosis between 30 
and 60%; and grade 3: steatosis >60%. Lobular  inflammation was graded 
on a four-point scale based on inflammatory foci per 20×: grade 0; 1 
with 1–2 foci; 2 with 3–4 foci; 3 with >4 foci. Fibrosis was staged on a 
five-point scale, stage 0: no fibrosis; stage 1: zone 3  perisinusoidal fibro-
sis; stage 2: perisinusoidal fibrosis and periportal fibrosis; stage 3: focal 
or extensive bridging fibrosis; stage 4: cirrhosis.
data analysis
Data are presented as mean values ± s.d. for continuous variables and 
frequencies for categorical variables. Bivariate relationship for measures 
with grade of steatosis and stage of fibrosis was evaluated using χ2-test 
for categorical variables. Spearman correlation coefficient and its P value 
for significance of correlation were calculated to assess the magnitude 
and direction of an association between two given measures based on 
their ordered ranks. For data that were highly skewed, we applied a 
natural log transformation to achieve normality and significance test-
ing on a log-transformed scale. The relative risks of developing steatosis 
and fibrosis associated with clinical measures were estimated using the 
odds ratios and their corresponding 95% confidence intervals through 
step-wise multiple logistic regression analysis. We used 5% as the cutoff 
for the probability of entering a variable in the model and removing a 
variable from the model. The probabilities were calculated using the 
Wald test. Deviance residuals were used to evaluate the goodness-of-fit, 
and likelihood ratio test was performed to compare the reduced model 
with the full model. All reported P values are based on two-sided tests. 
A two-sided P value <0.05 was considered significant. All analyses were 
performed using SAS statistical software (SAS Institute, Cary, NC).
results
clinical features and the metabolic syndrome
One hundred seventy nine patients listed for bariatric surgery 
have consented for this study. One hundred and four of the 
enrolled patients had satisfactory liver specimens, and their 
plasma samples were collected appropriately to be included 
in the analysis. Forty-nine patients were excluded because 
of suboptimal liver specimens (subcapsular specimens, burn 
artefacts), 24 because the plasma samples were not adequate 
for SLR analysis, and 2 patients did not undergo the bariatric 
procedure after intraoperative evidence of cirrhosis. Baseline 
demographic and metabolic features are summarized in 
Table 1. Females were 76% of the studied group. There was no 
significant age difference between the two genders. The mean 
BMI of the whole group was 46.2 ± 5.8, and females had sig-
nificantly lower BMI than males (45.5 ± 6 vs. 48.3 ± 4.8, P = 
0.03). Hyperlipidemia and hypertension were the most repre-
sented features of metabolic syndrome, both present in >60% 
of patients, and they were significantly correlated (r = 0.2, P = 
0.01). The mean HOMAIR index was 7.1 ± 10.6.
association between the plasma leptin, slr, and  
FlI values and the clinical parameters
The mean plasma leptin concentration was 43.7 ± 20.1 ng/ml. 
Leptin levels tended to be higher in women than men (46.3 ± 
18.2 vs. 35.6 ± 23.6 ng/ml, P = 0.02) and were significantly cor-
related with the BMI (r = 0.37, P < 0.0001), similarly to the data 
from previous reports (13,21,22). SLR was positively correlated 
with the presence of diabetes (r = 0.24, P = 0.01), whereas its 
derivative, the FLI was negatively correlated with this para-
meter (r = −0.2, P = 0.002) (Table 2). However, we did not find 
any significant correlations of SLR with the fasting glucose or 
insulin concentrations.
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association between the slr/FlI values and  
the histological grade/stage of liver disease
The main histological findings are summarized in Table 1. The 
majority of the patients had a steatosis degree between 10 and 
60%. Eighty-three percentage of patients had stage 0–1 fibro-
sis, the remaining 17% presented with stage 3 fibrosis. We did 
not observe any differences in the distribution of the disease 
severity between men and women. Steatosis was positively 
correlated with the HOMAIR index (r = 0.39, P < 0.0001) and 
with the presence of diabetes (r = 0.24, P = 0.015). In contrast 
to previous studies reporting a positive association between 
steatosis and circulating leptin concentrations (12,21); we 
did not observe any significant correlation between these two 
 parameters in this patient population.
As for the fibrosis stage, we found a positive correlation to the 
SLR values (r = 0.22, P = 0.02) (Figure 1), whereas its deriva-
tive, the FLI exhibited a negative trend toward a correlation with 
fibrosis, as expected (r = −0.18, P = 0.06). For the FLI, there was 
a negative trend toward a correlation with steatosis as well, how-
ever, the latter did not achieve statistical significance, either (P = 
0.054). In agreement with previous reports (12,13), there was no 
correlation between fibrosis and plasma leptin levels. A positive 
correlation was seen between the HOMAIR index and the stage 
of fibrosis (r = 0.24, P = 0.01), corroborating previous studies 
showing that diabetes and insulin resistance are the factors most 
closely associated with the severity of liver disease, in particular 
in patients with normal alanine aminotransferase (23,24).
The degree of inflammation was not significantly correlated 
with any of the clinical or biochemical variables we examined, 
but it was positively correlated with the stage of fibrosis (r = 
0.3, P = 0.001), consistent with a role for inflammation in the 
pathogenesis of hepatic fibrosis (25). Significant correlations 
are summarized in Table 2.
Stepwise regression analysis was performed to ascertain the 
predictors of steatosis among several independent variables. 
The independent variables included age, gender, BMI, pres-
ence of hypertension, hyperlipidemia, fasting plasma glucose, 
fasting plasma insulin, HOMAIR index, leptin, SLR, and FLI. 
All the independent variables were initially considered in the 
multiple regression analysis. The multiple logistic regression 
analysis revealed that the elevated insulin and decreasing levels 
of FLI were the significant predictors of steatosis after adjusting 
for the other variables. Backward elimination was carried out to 
determine which variables should be excluded from the fitted 
model using the likelihood ratio test. The final model included 
two significant predictors, elevated insulin (P = 0.0005), and 
decreasing levels of FLI (P = 0.031). The analysis also suggested 
that the combination of fasting insulin and decreasing levels 
of FLI still remained significant predictors of steatosis (overall 
P = 0.0021), after adjusting for age and gender (Table 3).
Similarly, stepwise logistic regression analysis was performed 
to identify independent predictors for the stage of fibrosis after 
controlling for other variables. The multiple logistic regression 
table 1 clinical and metabolic features of the 104 enrolled 
patients
Age 43.2 ± 9.2
Gender (F/M) 79/25 (76/24%)
BMI 46.2 ± 5.8
Hypertension 63 (61%)
Diabetes type 2 39 (37.5%)
HOMA index 7.1 ± 10.6
Hyperlipidemia 65 (63%)
Total cholesterol (mg/dl) 184 ± 40
LDL cholesterol (mg/dl) 115 ± 32.8
HDL cholesterol (mg/dl) 40 ± 11.8
Triglyceride (mg/dl) 157 ± 84
Leptin (ng/ml) 43.7 ± 20.1
Soluble leptin receptor (U/ml) 38.4 ± 28.4
Free leptin index (ng/U) 1.5 ± 1.1
Grade of steatosis
 <10% 23 (22%)
 10–29% 39 (38%)
 30–60% 38 (37%)
 >60% 4 (4%)
Grade of inflammation
 0 45 (43.3%)
 1 49 (47.1%)
 1.5 5 (4.8%)
 2 5 (4.8%)
Stage of fibrosis
 0 81 (78%)
 1 5 (5%)
 3 18 (17%)
Values are presented as mean ± s.d. or frequency (%).
HOMA, homeostasis model of assessment; HDL, high-density lipoprotein; 
LDL, low-density lipoprotein.
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Figure 1 Plasma soluble leptin receptor (SLR) concentrations and the 
stage of fibrosis. The levels of SLR were positively correlated with the 
stage of fibrosis in morbidly obese patients undergoing bariatric surgery 
(r = 0.22, P = 0.02). The dots represent patients with extreme values in 
the high end.
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analysis identified that BMI (P = 0.0439), inflammation (P = 
0.0017), and decreasing level of FLI (P = 0.0053) were the 
significant independent predictors for the stage of fibrosis. 
When we further adjusted for age and gender, the combination 
of decreasing FLI and inflammation remained significantly 
associated with fibrosis in this patient population (overall P = 
0.0002) (Table 4).
dIscussIon
In this study, we found that SLR was positively correlated with 
the stage of fibrosis in morbidly obese patients with insulin 
resistance or diabetes, whereas its derivative, FLI was a nega-
tive predictor. There was also a positive  correlation between 
 inflammation and the progression of fibrosis, supporting pre-
vious observations (26,27). SLR, thought to be mainly derived 
from the liver (17), is one of the main leptin-binding proteins in 
the plasma and it may regulate the levels of biologically active 
free leptin (28). SLR is generated by the proteolytic cleavage 
of the membrane-bound leptin receptor, ObRe (ectodomain 
shedding), a process which is regulated under various physi-
ological and pathophysiological conditions (29,30). Matrix 
 metalloproteinases, especially the ADAMTs (A Disintegrin 
and Metalloproteinase with Thrombospondin-1-like domains) 
group, were reported to be involved in the cleavage of SLR 
(31,32). The proteolytic activity of ADAMTs has been corre-
lated to stellate cells activation and, in vivo, to liver fibrogenesis 
table 3 Multiple logistic regression analysis for predictors 
of steatosis
Factors Odds ratio 95% CI P value Overall P value
Final model
 FLI 0.58 0.35–0.95 0.0316 0.0003
 Insulin 3.98 1.83–8.66 0.0005
Final model adjusted for age and gender
 FLI 0.61 0.36–1.02 0.0613 0.0021
 Insulin 3.78 1.72–8.31 0.0009
Steatosis was considered as a categorical variable, and four categories of steato-
sis were included in the analysis (<10% steatosis, 10–29%, 30–60%, >60%).
CI, confidence interval; FLI, free leptin index.
table 4 Multiple logistic regression analysis for predictors 
of fibrosis
Factors Odds ratio 95% CI P value
Overall 
P value
Final model
 FLI 0.31 0.14–0.71 0.0053 0.0002
 BMI 1.10 1.00–1.21 0.0439
 Inflammation 4.48 1.76–11.40 0.0017
Final model adjusted for age and gender
 FLI 0.34 0.14–0.82 0.0169 0.0002
 BMI 1.09 0.98–1.21 0.1055
 Inflammation 4.93 1.79–13.55 0.0020
Fibrosis was considered as a categorical variable, and the stages of fibrosis 
included in the analysis were stages 0, 1, and 3. One case of stage 2.5 was 
incorporated with stage 3.
CI, confidence interval; FLI, free leptin index.
table 2 Bivariate correlations between features of the metabolic syndrome, leptin, soluble leptin receptor (slr), and free leptin 
index (FlI) and the histological parameters of nonalcoholic fatty liver disease severity as calculated by the spearman correlation 
(coefficient and P value)
Parameters Fibrosis Steatosis Inflammation BMI DM2 HOMA Hypertension Hyperlipidemia
Steatosis 0.13
0.18
Inflammation 0.3
0.001
0.12
0.22
BMI 0.13
0.17
–0.03
0.76
0.05
0.54
DM2 0.17
0.07
0.24
0.015
0.02
0.84
0.1
0.3
HOMA 0.24
0.01
0.39
<0.0001
0.008
0.92
0.09
0.33
0.43
<0.0001
Hypertension 0.01
0.89
0.10
0.32
–0.002
0.97
–0.01
0.85
0.38
<0.0001
0.26
0.007
Hyperlipidemia –0.003
0.97
0.13
0.20
–0.03
0.7
0.01
0.9
0.16
0.09
0.13
0.17
0.24
0.01
Leptin –0.06
0.52
–0.17
0.09
–0.004
0.96
0.37
<0.0001
–0.15
0.1
0.002
0.98
–0.1
0.09
–0.02
0.78
SLR 0.22
0.02
0.12
0.23
0.03
0.73
–0.1
0.28
0.24
0.01
–0.08
0.4
0.09
0.32
–0.02
0.79
FLI –0.18
0.06
–0.16
0.10
–0.007
0.93
0.3
0.002
–0.29
0.002
0.04
0.64
–0.14
0.13
0.01
0.89
Significant P values are depicted in bold.
DM2, type 2 diabetes mellitus; HOMA, homeostasis model of assessment.
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(32,33). As activated stellate cells in the liver produce matrix 
metalloproteinases, it is conceivable that the rise in plasma 
SLR may reflect matrix metalloproteinase activity and fibro-
genesis in the liver. Indeed, recent studies in patients with cir-
rhosis from various etiologies described increasing SLR and 
lower FLI, similarly to our study (34). As leptin is thought to 
be a profibrogenic cytokine in vitro, one may expect increasing 
free leptin levels in cirrhotic patients. There could be several 
reasons for this contradiction: first, we do not know whether 
the peripheral SLR/leptin levels reflect the sinusoidal concen-
trations, second, leptin may play different roles at the initia-
tion and progression phases of fibrosis. Detailed mechanistic 
 studies are required to elucidate these aspects.
Increasing plasma SLR levels found in obese, diabetic patients 
could point to the development of leptin resistance (15). 
Leptin resistance is an important phenomenon as it causes fur-
ther dysregulation of metabolic and inflammatory pathways, 
worsening insulin resistance, ultimately leads to progressive 
organ injury in obese patients with the metabolic syndrome 
(35). Recently it was described that in the liver-specific insulin 
receptor knockout mice there was about an 80-fold increase 
in circulating SLR, pointing to the importance of intact insu-
lin signaling in the liver in the modulation of leptin receptor 
expression (36).
Our study was consistent with previous findings concern-
ing the positive correlation between leptin and BMI (21). 
According to earlier data, we have not seen any significant 
correlation between the plasma leptin levels and fibrosis 
(12,21,37). Our study population consisted of morbidly obese 
adult patients with insulin resistance, who are frequently 
asymptomatic but have under recognized metabolic complica-
tions and liver disease. The patients in our study were relatively 
younger, with generally less advanced liver damage than usu-
ally is seen in patients referred to the hepatology clinic, yet our 
patients represent a significant study group. Patients referred 
with NASH often have well-established cirrhotic stage disease, 
and studying markers contributing to disease activity in this 
group sometimes is not feasible. Also, in our study there were 
more women than men, whereas other studies have reported a 
higher prevalence of NASH in men (1,38). We recognize that 
larger studies with more patients with advanced NASH are 
needed to validate these findings.
Future studies at a molecular level are needed to define 
the causal correlation between markers of fibrogenic activity, 
inflammation, and the circulating SLR in patients with obesity 
and NASH.
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